Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$20.16

52W Range

$16.65 - $31.26

50D Avg

$20.16

200D Avg

$24.40

Market Cap

$894.65M

Avg Vol (3M)

$604.01K

Beta

0.90

Div Yield

-

AMPH Company Profile


Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2,028

IPO Date

Jun 25, 2014

Website

AMPH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 20
Epinephrine$70.64M--
Other-$19.15M-
Product-$712.81M-
Active Pharmaceutical Ingredient Segment--$18.48M

Fiscal year ends in Dec 25 | Currency in USD

AMPH Financial Summary


Dec 25Dec 24Dec 23
Revenue$719.89M$731.97M$644.39M
Operating Income$140.40M$205.42M$196.99M
Net Income$98.09M$159.52M$137.54M
EBITDA$140.40M$277.31M$240.29M
Basic EPS$2.10$3.29$2.85
Diluted EPS$2.03$3.06$2.60

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 08, 26 | 12:00 AM
Q4 25Feb 26, 26 | 5:00 PM
Q3 25Nov 08, 25 | 5:00 PM

Peer Comparison


TickerCompany
BBNXBeta Bionics, Inc.
EMBCEmbecta Corp.
HROWHarrow Health, Inc.
AHCOAdaptHealth Corp.
DVAXDynavax Technologies Corporation
CVACCureVac N.V.
SNDXSyndax Pharmaceuticals, Inc.
COLLCollegium Pharmaceutical, Inc.
INBXInhibrx Biosciences, Inc.
PCRXPacira BioSciences, Inc.